Press Release: Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting FARMINGTON HILLS, Mich., April 22, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) ("Ocuphire"), a clinical-st
Dow JonesApr 22 08:00 ET
Ocuphire Pharma Incentivizes Director Pepose With Stocks and Options
TipRanksApr 17 16:32 ET
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersOntrak (NASDAQ:OTRK) shares increased by 18.7% to $0.45 during Thursday's after-market session. The company's market cap stands at $18.9 million. Ocuphire Pharma (NASDAQ:OCUP) stock rose 7.82%
BenzingaApr 11 16:31 ET
Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment
Ocuphire Pharma (OCUP) enrolled the first patient in the phase 3 trial of its Phentolamine Ophthalmic Solution 0.75% for the treatment of decreased visual acuity under low light conditions following k
MT NewswiresApr 11 14:28 ET
Express News | First Patient Enrolled in Lynx-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (Ps) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
Moomoo 24/7Apr 11 10:03 ET
Analysts Offer Insights on Healthcare Companies: Smith & Nephew Snats (SNN), Ocuphire Pharma (OCUP) and Vertex Pharmaceuticals (VRTX)
TipRanksApr 2 07:20 ET
Ocuphire Announces the US Commercial Launch of RYZUMVl (Phentolamine Ophthalmic Solution 0.75%) by Its Partner Viatris
Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disor
BenzingaApr 1 07:17 ET
Ocuphire Pharma Engages Investors With Presentation Update
TipRanksMar 27 16:44 ET
Design Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders int
BenzingaMar 26 07:37 ET
Ocuphire Pharma(OCUP.US) Officer Buys US$4,100 in Common Stocks
$Ocuphire Pharma(OCUP.US)$ Officer SCHACHLE JOSEPH K purchased 2,000 shares of Common Stocks on Mar 21, 2024 at an average price of $2.05 for a total value of $4,100.Source: Announcement What is state
moomoo NewsMar 25 17:28 ET
Ocuphire Pharma(OCUP.US) Officer Buys US$21,000 in Common Stocks
$Ocuphire Pharma(OCUP.US)$ Officer Jhaveri Nirav S. purchased 10,000 shares of Common Stocks on Mar 21, 2024 at an average price of $2.1 for a total value of $21,000.Source: Announcement What is state
moomoo NewsMar 25 17:23 ET
Ocuphire Pharma(OCUP.US) Officer Buys US$49,050 in Common Stocks
$Ocuphire Pharma(OCUP.US)$ Officer Magrath George purchased 25,000 shares of Common Stocks on Mar 18, 2024 at an average price of $1.962 for a total value of $49,050.Source: Announcement What is state
moomoo NewsMar 20 17:01 ET
Ocuphire Pharma Is Maintained at Buy by Alliance Global Partners
Ocuphire Pharma Is Maintained at Buy by Alliance Global Partners
Dow JonesMar 20 08:20 ET
Alliance Global Partners Maintains Buy on Ocuphire Pharma, Lowers Price Target to $20
Alliance Global Partners analyst James Molloy maintains Ocuphire Pharma with a Buy and lowers the price target from $24 to $20.
Analyst UpgradesMar 20 08:10 ET
Earnings Update: Ocuphire Pharma, Inc. (NASDAQ:OCUP) Just Reported And Analysts Are Trimming Their Forecasts
Yahoo FinanceMar 13 06:41 ET
Express News | HC Wainwright & Co. Reiterates Buy on Ocuphire Pharma, Maintains $20 Price Target
Moomoo 24/7Mar 11 07:36 ET
Ocuphire Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/11/2024 895.02% HC Wainwright & Co. → $20 Reiterates Buy → Buy 11/14/2023 895.02% HC Wainwright & Co. →
BenzingaMar 11 07:34 ET
Analysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Merus (MRUS) and Eli Lilly & Co (LLY)
TipRanksMar 11 07:10 ET
Buy Rating Affirmed for Ocuphire Pharma on Promising APX3330 Progress for Diabetic Retinopathy Treatment
TipRanksMar 11 06:28 ET
Ocuphire Pharma Full Year 2023 Earnings: Misses Expectations
Yahoo FinanceMar 10 09:47 ET
No Data
No Data